-
Advances of Drug-Loaded Microsphere Technology for Targeted Immunotherapy Against Prostate Cancer
19 Sep 2025 16:43 GMT
… collaboration across clinical medicine, data science, … Drug Delivery Applications: An Overview of Recent Advances. Pharmaceutics … al. Intradermal DNA vaccination combined with dual … FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment …
-
Breast Cancer Gene (BRCA) Mutations Treatment Market to Reach USD $6.56 Billion by 2029 at 7% CAGR
10 Sep 2025 06:43 GMT
… therapies are unique medical treatments that fight cancer … AG
• GSK plc
• Janssen Biotech Inc.
• Astellas Pharma Inc. … ., Inc. launched LYNPARZA (olaparib) in August 2022, following … Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies, Adoptive …
-
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
09 Sep 2025 10:00 GMT
… Biosplice”), a clinical-stage biotechnology company pioneering advancements in small … , M.D., Chief Medical Officer at Biosplice. “ …
An upcoming combination trial with olaparib in BRCA-mutated or … treatment of advanced solid tumors in two clinical trials. …
-
Key takeaways from the COMRADE trial in CRPC, with Rana McKay, MD
07 Sep 2025 11:24 GMT
… McKay is a genitourinary medical oncologist at the University … symptoms. Drug discontinuation rates were about 24% with [olaparib] … into the treatment landscape for mCRPC?
This trial really … Clinical Trials Network] ETCTN as an investigator-initiated trial …
-
Dr McKay on the Rationale for Evaluating Radium-223 Plus Olaparib in mCRPC With Bone Metastases
05 Sep 2025 22:06 GMT
… professor in the Departments of Medicine and Urology at the University … , discussed the rationale for evaluating olaparib (Lynparza) in combination with the … phase 2 COMRADE trial (NCT03317392).
McKay began by stating that mCRPC represents …
-
Dr Van Tine on Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma
03 Sep 2025 05:44 GMT
… . Milliken Department of Medicine Division of Oncology at … Washington University School of Medicine, discussed efficacy data … 47;3 Alliance A092104 trial (NCT05432791) investigating olaparib (Lynparza) plus … total, 44.2% of treatment cycles in the experimental …
-
January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
29 Aug 2025 20:22 GMT
… available information.
Lynparza (olaparib)
Drug-induced liver injury
FDA determined that no action … Counseling Information", and "Medication Guide" sections of the … container label, carton label, "Medication Guide", and sections of …
-
The jab to fight 15 forms of cancer – and the trials which may revolutionise treatment
30 Aug 2025 14:06 GMT
… via a vaccine, called nivolumab, in a treatment that will … cancer
The trial combined a PARP inhibitor drug called olaparib with chemotherapy … with over-the-counter medications.
Early diagnosis can be … individuals to go to the doctor. Recruitment of men and …
-
Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial
28 Aug 2025 20:13 GMT
… Overall, the trial showed that reduced-dose olaparib (Lynparza) combined … McKay is a GU medical oncologist at the University … , grade 3 or higher treatment-related adverse events (TRAEs) … 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. …
-
Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma
29 Aug 2025 00:02 GMT
… Oncology Fellowship Program, and medical director of patient education … #47;3 Alliance A092104 trial (NCT05432791) investigating olaparib (Lynparza) plus temozolomide … investigational combination of olaparib plus temozolomide or treatment according to …